

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel,¹ Myriam Labopin,^{2,3} Gerard Socié,⁴ Dietrich Beelen,⁵ Paul Browne,⁶ Liisa Volin,⁷ Slawomira Kyrz-Krzemien,⁸ Ibrahim Yakoub-Agha,⁹ Mahmoud Aljurf,¹⁰ Depei Wu,¹¹ Mauricette Michallet,¹² Renate Arnold,¹³ Mohamad Mohty^{2*} and Arnon Nagler^{3,14*}

¹Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland; ²Hospital St. Antoine, Paris, France; ³Acute Leukemia Working Party of the EBMT; ⁴Hospital St. Louis, Paris, France; ⁵University Hospital, Essen, Germany; ⁶St. James's Hospital - Trinity College, Dublin, Ireland; ⁷Helsinki University Central Hospital, Finland; ⁸Silesian Medical University, Katowice, Poland; ⁹University Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research, International Center, Lille, France; ¹⁰King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia; ¹¹First Affiliated Hospital of Soochow University, Suzhou, China; ¹²Centre Hospitalier Lyon Sud - Service Hématologie, Lyon, France; ¹³Charité Universitätsmedizin Berlin - Campus Virchow Klinikum Berlin, Germany and ¹⁴Chaim Sheba Medical Center, Tel-Hashomer, Israel

**MM and AN contributed equally to this work*

©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2016.145631

Received: March 3, 2016.

Accepted: September 22, 2016.

Pre-published: September 29, 2016.

Correspondence: sgiebel@io.gliwice.pl

Supplemental Table 1: Results of alloHSCT for patients with Philadelphia-positive ALL.

Changes over time in a period 1993-2012

Period	RI (%, 95%CI)	NRM (%, 95%CI)	LFS (%, 95%CI)	OS (%, 95%CI)
1993-2002	40.7 (34 - 47.3)	25.1 (19.5 - 31.2)	34.2 (27.7 - 40.6)	45.3 (38.5 - 52.1)
2003-2007	29.7 (25.6 - 33.9)	28.4 (24.4 - 32.6)	41.8 (37.3 - 46.4)	54.6 (50 - 59.2)
2008-2012	22.9 (19.4 - 26.6)	19.7 (16.5 - 23.2)	57.1 (52.9 - 61.4)	67.9 (63.9 – 72)
<i>P</i> value	<0.0001	0.02	<0.0001	<0.0001

RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; NRM, non-relapse mortality; alloHCT allogeneic hematopoietic cell transplantation; MSD, matched sibling donor; URD, unrelated donor; CI, confidence interval

Supplemental Table 2: Results of alloHCT for patients with Philadelphia-negative ALL.
Changes over time in a period 1993-2012

a) Univariate analysis for MSD-HCT

Period	RI (%, 95%CI)	NRM (%, 95%CI)	LFS (%, 95%CI)	OS (%, 95%CI)
1993-2002	29.6% (22.9 - 36.5)	16% (11 - 21.8)	54.5% (47 - 61.9)	62.5% (55.3 - 69.7)
2003-2007	24.7% (20 - 29.8)	13.3% (9.7 - 17.4)	61.9% (56.3 - 67.4)	70.6% (65.4 - 75.9)
2008-2012	23% (18 - 28.5)	13% (9.1 - 17.6)	63.9% (57.8 - 70)	70.9% (65 - 76.8)
<i>P</i> value	0.2	0.6	0.04	0.01

b) Univariate analysis for URD-HCT


Period	RI (%, 95%CI)	NRM (%, 95%CI)	LFS (%, 95%CI)	OS (%, 95%CI)
1993-2002	22.1% (13 - 32.6)	20.6% (11.9 - 30.9)	57.4% (45.6 - 69.1)	63.2% (51.8 - 74.7)
2003-2007	22.2 % (17.4 - 27.5)	22% (17.2 - 27.2)	55.5% (49.5 - 61.6)	60.7% (54.8 - 66.7)
2008-2012	20.1 % (15.6 - 25.1)	20.6% (16.1 - 25.4)	59.3 % (53.5 - 65.1)	64.8% (59.1 - 70.5)
<i>P</i> value	0.9	0.64	0.83	0.76

c) Multivariate analysis


	Factor	HR (95% CI)	<i>P</i>
NRM	Year of alloHCT	0.98 (0.95-1.01)	0.17
	Recipient age (per 10 years)	1.35 (1.11-1.52)	<0.00001
	MSD vs. URD	1.59 (1.25-2.03)	0.0002
Relapse	Year of alloHCT	0.97 (0.95-0.99)	0.02
	Recipient age (per 10 years)	1.03 (0.93-1.14)	0.59
	MSD vs. URD	0.95 (0.76-1.17)	0.61
Treatment failure	Year of alloHCT	0.97 (0.96-0.99)	0.006
	Recipient age (per 10 years)	1.16 (1.08-1.26)	0.0001
	MSD vs. URD	1.19 (1.01-1.4)	0.03
Overall mortality	Year of alloHCT	0.97 (0.95-0.99)	0.001
	Recipient age (per 10 years)	1.22 (1.12-1.32)	<0.00001
	MSD vs. URD	1.27 (1.07-1.5)	0.006

RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; NRM, non-relapse mortality; alloHCT allogeneic hematopoietic cell transplantation; MSD, matched sibling donor; URD, unrelated donor; HR, hazard ratio; CI, confidence interval

Supplemental Fig. 1. Leukemia-free survival (LFS) of patients with Philadelphia-positive ALL treated with alloHSCT. Changes over time in the period 1993-2012



Supplemental Fig. 2. Leukemia-free survival (LFS) for patients with Philadelphia-positive ALL compared to Philadelphia-negative ALL treated with alloHSCT the period 2008-2012



Supplemental Fig. 3. Leukemia-free survival (LFS) according to type of donor for alloHSCT performed in the period 2008-2012

